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Rhabdomyosarcoma (RMS) is a common paediatric soft tissue sarcoma that resembles developing foetal skeletal muscle. Tumours of
the alveolar subtype frequently harbour one of two characteristic translocations that juxtapose PAX3 or PAX7, and the forkhead-
related gene FKHR (FOXO1A). The embryonal subtype of RMS is not generally associated with these fusion genes. Here, we have
quantified the relative levels of chimaeric and wild-type PAX transcripts in various subtypes of RMS (n¼34) in order to assess the
relevance of wild-type PAX3 and PAX7 gene expression in these tumours. We found that upregulation of wild-type PAX3 is
independent of the presence of either fusion gene and is unlikely to contribute to tumorigenesis. Most strikingly, upregulated PAX7
expression is almost entirely restricted to cases without PAX3-FKHR or PAX7-FKHR fusion genes and may contribute to
tumorigenesis in the absence of chimaeric PAX transcription factors. Furthermore, as myogenic satellite cells are known to express
PAX7, this pattern of PAX7 expression suggests this cell type as the origin of these tumours. This is corroborated by the detection of
MET (c-met) expression, a marker for the myogenic satellite cell lineage, in all RMS samples expressing wild-type PAX7.
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Rhabdomyosarcoma (RMS) is the most common soft tissue
sarcoma of childhood, accounting for up to 8% of all cases of
childhood cancer (Cornelison and Wold, 1997). This embryonal
muscle cancer resembles normal preinnervated foetal skeletal
muscle, both morphologically and in its expression of muscle-
specific genes (including the muscle regulatory factor (MRF)
family and skeletal muscle-specific structural proteins). There are
distinct histological subtypes of RMS that differ in their clinical
presentation and behaviour: the embryonal subtype (ERMS) is
more common in young children and has a better prognosis,
whereas the alveolar subtype (ARMS) is more common in
adolescents, is frequently metastatic at diagnosis, and has a worse
prognosis. In addition, a rare pleomorphic subtype (PRMS)
predominates in adults, among whom RMS is relatively infrequent
(Hollowood and Fletcher, 1994).
The histogenesis of RMS is unclear, although it is generally
believed to originate from persistent foetal rhabdomyoblasts that
have failed to undergo normal differentiation. Studies of expres-
sion patterns of myogenic genes have failed to demonstrate any
differences in extent of myogenic differentiation between the two
main subtypes, ERMS and ARMS. However, comparative genomic
hybridisation (CGH) analysis has shown that ERMS frequently
exhibits gains or losses of specific whole chromosomes, whereas
ARMS is characterised by the presence of regions of genomic
amplification (Weber-Hall et al, 1996; Gordon et al, 2001). The
finding of consistent reciprocal chromosomal translocations only
in ARMS has suggested a biological basis for the difference in
tumour aggressiveness. Alveolar tumours typically harbour one of
the two characterised chromosomal translocations that juxtapose
PAX gene family member PAX3 or PAX7 with the Forkhead-related
FKHR (FOXO1A) gene. The t(2;13)(q35;q14) translocation results
in the PAX3-FKHR fusion gene, and the less common
t(1;13)(p36;q14) produces the PAX7-FKHR fusion gene. Both
translocations generate an in-frame fusion between the undis-
rupted PAX gene DNA-binding domain and the transactivation
domain of the FKHR gene.
During normal myogenesis, PAX3 is expressed in migrating
myoblasts and is believed to inhibit their differentiation until they
reach their destination. It has been suggested that dysregulated
expression of PAX3, and/or its normal target genes, is involved in
RMS tumorigenesis (Bober et al, 1994; Goulding et al, 1994;
Epstein et al, 1996). The chimaeric PAX3-FKHR protein has been
studied in vitro and shown to retain wild-type PAX3 DNA-binding
specificity, but with enhanced transcriptional activation. PAX3-
FKHR is therefore a more powerful transcription factor than wild-
type PAX3. (Fredericks et al, 1995; Bennicelli et al, 1996; Anderson
et al, 1999; Merlino and Helman, 1999). PAX3-FKHR transforms
chicken embryo fibroblasts, although wild-type PAX3 is unable to
do so (Schiedler et al, 1996), and PAX3-FKHR inhibits the
differentiation of the C2C12 murine myoblastic cell line to a greater
extent than wild-type PAX3 (Epstein et al, 1995). This suggests that
enhanced PAX3 activity, through increased transcription levels
and transcriptional activity of the PAX3-FKHR chimaeric protein,
may be contributing to the oncogenic phenotype of RMS. PAX7
expression in normal myogenesis is concurrent with PAX3
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sexpression in myoblasts in the dermomyotome, although PAX7
expression does not persist in migrating myoblasts. It has been
shown that the PAX7-FKHR fusion gene is frequently amplified in
ARMS, suggesting that increased gene dosage may be important in
controlling its altered function (Barr et al, 1996; Weber-Hall et al,
1996; Anderson et al, 1999; Barr, 1999, 2001; Fitzgerald et al, 2000).
PAX3 and PAX7 appear to have a high degree of functional
redundancy in normal myogenesis (Mansouri, 1998), although
recent work has proposed that expression of PAX7, and not PAX3, is
required for the specification and maintenance of myogenic satellite
cells, a distinct lineage of myoblastic precursor cells responsible for
the postnatal growth, repair and maintenance of skeletal muscle
(Seale et al, 2000). Expression of PAX3 and PAX7 has previously
been detected in RMS cell lines (Barr et al,1 9 9 9 ) ,h e r ew eh a v e
measured levels of expression of the PAX genes and their chimaeric
PAX-FKHR derivatives in primary RMS samples. The observations
that PAX3-FKHR is a more potent transcription factor than PAX3,
and that PAX7-FKHR is frequently amplified in RMS cases, suggest
that there may be a ‘dose’ effect of increased PAX3/PAX7 activity in
RMS (Ginsberg et al, 1998). Hence, in tumours without PAX3/7-
FKHR fusion genes, it is possible that mechanisms other than those
associated with PAX3/7-FKHR fusion genes cause increased
expression of wild-type PAX genes, with the same tumorigenic
outcome as expression of the chimaeric proteins. Additionally,
levels of PAX gene expression may reflect the cellular origin and
stage of myogenic differentiation associated with the tumour.
Real-time PCR accurately measures the copy number of a
specific mRNA species in a small sample of total RNA (o1mg),
and is useful for analysis of gene expression in primary RMS
tumours because samples are seldom large enough for protein
analysis. We used this technique to measure mRNA levels for wild-
type PAX3, PAX7, PAX3-FKHR and PAX7-FKHR in RMS, to
determine whether higher levels of wild-type PAX3 and PAX7 are
observed in tumours that do not express PAX3-FKHR and PAX7-
FKHR chimaeric transcripts. Expression of a putative target gene
for upregulation by PAX3 and PAX3-FKHR, the oncogene MET,
has also been measured by RT–PCR to determine whether
upregulation of wild-type PAX3/7 activity in the absence of
PAX3/7-FKHR fusion genes may be having a downstream effect.
METHODS AND MATERIALS
Preparation of cDNA from RMS samples
The RMS samples have been previously characterised and
described (Anderson et al, 2001). Total RNA was prepared from
frozen RMS primary tumour samples and cell lines using Trizol
(Life Technologies, Inc., Scotland, UK) according to the manu-
facturer’s instructions. cDNA was synthesised from 1mg total RNA
using reverse transcriptase ‘Superscript’ (Life Technologies) and
random hexamers (Life Technologies). To determine cDNA
integrity, PCR was used to detect the ubiquitous housekeeping
gene GAPDH (primer 1: 50-CGGGAAGCTTGTGATCAATGG-30,
primer 2: 50-GGCAGTGATGGCATGGACTG-30, Tm¼551C,
[Mg
2þ]¼2.0mM, product size¼358bp, 35 cycles).
Real-time PCR to detect levels of PAX3, PAX7, PAX3-FKHR
and PAX7-FKHR mRNA
A multiplex TaqMan
s reaction was used to measure levels of the
gene of interest, and of 18S rRNA. The gene of interest was
detected using a FAM/TAMRA-labelled probe, and the rRNA
internal control was detected using a VIC/TAMRA-labelled probe.
The reaction was performed in 25mlo f1  TaqMan
s Universal
PCR Mix (Applied Biosystems, Foster City, CA, USA) containing
primers, probes and cDNA template. Primers and probes were
designed to amplify across the PAX-FKHR breakpoint in the fusion
genes, and the equivalent region of the wild-type PAX3 and PAX7
genes, and also to amplify across an exon/exon boundary to ensure
no genomic DNA would be amplified. Optimal primer and probe
concentrations were determined empirically. Table 1 shows
primers and probes used for the reactions. Cycling parameters
used were 2min at 501C, 10min at 951C, and then 15s at 951C
followed by 1min at 601C for 40 cycles. The reactions were carried
out on the ABI Prism 7700 DNA sequencer. Relative expression of
the gene of interest and 18S rRNA was determined from a standard
curve generated from a dilution series of known positive RMS
samples. The RD RMS cell line (RDCL) (American Type Cell
Culture, Manassas, VA, USA) was used as a positive control for
both PAX3 and PAX7 expression, as expression of both the genes
was readily detectable in this cell line by conventional RT–PCR (35
cycles). RMS cell line Rh30 was used as a positive control for
PAX3-FKHR expression, and in the absence of known RMS cell
lines expressing the PAX7-FKHR fusion gene, a primary tumour
(sample 6) with a known t(1;13) translocation was used as a
positive control for PAX7-FKHR expression. Expression of the
fusion genes was readily detectable in these positive controls by
RT–PCR (35 cycles). cDNA (0.1ml) was used in each Real-Time
PCR reaction, and level of relative expression for each gene of
interest in each sample was measured in four independent
experiments. Translocation status is shown for each tumour and
had been previously determined by a combination of three
methods (cytogenetics, interphase fluorescent in situ hybridisation
and RT–PCR) in a previous study characterising this cohort of
samples (Anderson et al, 2001).
Table 1 Primers and probes used to detect PAX3, PAX7, PAX3-FKHR and PAX7-FKHR expression by real-
time PCR
Gene Sequence Concentration (nM)
PAX3 Primer 1: 50-CACCAGGCATGGATTTTCC-30 50
Primer 2: 50-TTGTCAGGAGTCCCATTACCT-30 50
Probe: 50-CACCATTGGCAATGGCCTCTCA-30 50
PAX7 Primer 1: 50-CCACAGCTTCTCCAGCTACTCTG-30 300
Primer 2: 50-GGGTTGCCCAAGATGCTC-30 300
Probe: 50-CCGGTCAGCAACGGCCTGTCT-30 100
PAX3-FKHR Primer 1: 50-AGGCATGGATTTTCCAGCTATA-30 50
Primer 2: 50-GGGACAGATTATGACGAATTGAATT-30 300
Probe: CACCATTGGCAATGGCCTCTCA-30 50
PAX7-FKHR Primer 1: 50-TCTGCCTACGGAGCCCG-30 300
Primer 2: 5-GGGACAGATTATGACGAATTGAATT-30 300
Probe: 50-CCGGTCAGCAACGGCCTGTCT-30 100
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The TaqMan
s ribosomal RNA control reagents (Applied Biosys-
tems) are designed to detect the 18S rRNA gene in a diverse range
of eukaryotes. Levels of 18S rRNA were detected in each sample in
tandem with detection of the gene of interest, and used as a control
for the total amount of cDNA added to the reaction.
RT–PCR to detect MET in RMS samples
Primers for the MET gene were designed to amplify across an
exon/exon boundary to prevent amplification of genomic DNA.
The primers were chosen to lie in regions of the sequence not
showing significant homology with other known gene family
members. Primers used were 50-TGAATACTGCAGAC-
CAATGTGCTAATAGAT-30 (forward primer) and 50-TAGTGATA-
GATACTGTTCCCTTGTAGCTGC-30 (reverse primer), (Oswel,
University of Southampton, UK), Tm¼531C, 40 cycles. A total
volume of 25ml was used for each PCR (0.5mM dNTPs, 0.5mM
forward and reverse primers, 2.0mM Mg, 0.1ml Taq polymerase
and 1.0ml cDNA). To confirm specificity of the PCR reactions, the
amplified cDNA fragment (240bp) was digested with restriction
enzyme HaeIII and DNA fragments (147, 93bp) were resolved on a
2.5% agarose gel.
RESULTS
Expression of each of the wild-type PAX3 and PAX7 genes and the
two fusion genes PAX3-FKHR and PAX7-FKHR was measured by
quantitative real-time PCR in 34 primary RMS tumours and in
three RMS cell lines. Expression levels were quantified relative to
expression in the RD cell line (RDCL) for PAX3 and PAX7, the
Rh30 cell line for PAX3-FKHR and a primary tumour (sample 6)
for PAX7-FKHR, since no cell line expressing this fusion gene was
available. Table 2 shows the average expression levels determined
in four independent experiments. Since our hypothesis is that the
mechanism of enhanced PAX3 and/or PAX7 activity will vary
according to whether the tumour contains a PAX3/7-FKHR fusion
gene, tumours are grouped by translocation status rather than
histological subtype. To give an overview of how the levels of
expression of the four genes relate to each other, relative PAX3
levels (Figure 1A) are compared to relative PAX3-FKHR levels
Table 2 Real-time data for PAX3, PAX3-FKHR, PAX7 and PAX7-FKHR
Pax3 Pax3FKHR Pax7 Pax7FKHR
Sample I.D. Trans Diagnosis Mean s.d. Mean s.d. Mean s.d. Mean s.d.
6 1:13 ARMS 0.28 0.08 0.00 0.00 1.61 0.90 1.00 0.20
8 1:13 ARMS 0.00 0.00 0.00 0.00 11.90 19.96 2.08 0.48
7 1:13 ARMS 0.00 0.00 0.00 0.00 0.84 0.75 0.75 0.20
30 2:13 ARMS 0.00 0.00 2.80 0.86 0.00 0.00 0.00 0.00
43 2:13 ARMS 0.28 0.13 1.29 0.08 1.84 1.51 0.00 0.00
35 2:13 ARMS 0.00 0.00 1.20 0.75 0.00 0.00 0.00 0.00
31 2:13 ARMS 0.85 0.27 0.87 0.11 0.00 0.00 0.00 0.00
40 2:13 ARMS 1.32 0.05 3.08 0.41 2.43 1.10 0.00 0.00
32 2:13 ARMS 1.15 0.15 2.23 0.18 15.67 8.63 0.00 0.00
12 2:13 ERMS 0.00 0.00 0.34 0.42 0.00 0.00 0.00 0.00
38 2:13 RMS-nos 0.25 0.07 0.52 0.22 0.00 0.00 0.00 0.00
Rh30 2:13 Cell Line 0.18 0.07 1.00 0.04 0.00 0.00 0.00 0.00
4 Neither RMS-nos 1.45 0.58 0.00 0.00 18.04 7.92 0.00 0.00
3 Neither ARMS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
110 Neither ARMS 0.00 0.00 0.00 0.00 3.80 2.51 0.00 0.00
74 Neither ARMS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
88 Neither ARMS 0.02 0.03 0.00 0.00 126.71 51.76 0.00 0.00
61 Neither ARMS 0.00 0.00 0.00 0.00 501.39 138.76 0.00 0.00
87 Neither ARMS 0.33 0.17 0.00 0.00 0.00 0.00 0.00 0.00
107 Neither ARMS 0.03 0.02 0.00 0.00 45.57 17.14 0.00 0.00
25 Neither ERMS 0.00 0.00 0.00 0.00 228.49 111.33 0.00 0.00
85 Neither ERMS 0.00 0.00 0.00 0.00 51.02 14.35 0.00 0.00
36 Neither ERMS 1.20 0.22 0.00 0.00 211.67 62.47 0.00 0.00
82 Neither ERMS 0.02 0.02 0.00 0.00 88.59 45.35 0.00 0.00
53 Neither ERMS 0.00 0.00 0.00 0.00 40.22 50.43 0.00 0.00
28 Neither ERMS 0.00 0.00 0.00 0.00 29.59 27.12 0.00 0.00
77 Neither ERMS 0.00 0.00 0.00 0.00 2.06 1.67 0.00 0.00
79 Neither ERMS 1.87 0.40 0.00 0.00 110.51 64.14 0.00 0.00
56 Neither ERMS 0.35 0.17 0.00 0.00 179.96 44.47 0.00 0.00
100 Neither ERMS 0.08 0.03 0.00 0.00 0.04 0.04 0.00 0.00
98 Neither ERMS 0.13 0.08 0.00 0.00 0.65 0.67 0.00 0.00
HX170 Neither Cell Line 0.58 0.07 0.00 0.00 0.00 0.00 0.00 0.00
RDCL Neither Cell Line 1.00 0.18 0.00 0.00 1.00 0.24 0.00 0.00
99 Neither PRMS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
97 Neither PRMS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
101 Neither PRMS 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
95 Neither PRMS 0.00 0.00 0.00 0.00 0.33 0.47 0.00 0.00
Mean values and standard deviations (s.d.) are shown for each gene and each sample. Translocation status (‘Trans’) and histological diagnosis are shown. ARMS¼alveolar RMS,
ERMS¼embryonal RMS, PRMS¼pleomorphic RMS, RMS-nos¼RMS not otherwise specified. Positive values are shaded.
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s(Figure 1B), relative PAX7 levels (Figure 1C) and relative PAX7-
FKHR levels (Figure 1D).
Among the ERMS and ARMS, there was no clear pattern for
wild-type PAX3 mRNA expression, detected in 16 out of 30
primary ERMS and ARMS tumour samples, nor was there any
correlation with the presence of PAX3/7-FKHR fusion genes
(Figure 1A, B and D). By contrast, PAX7 mRNA expression
corresponded to translocation status rather than histological
subtype, with PAX7 expression detected in both ARMS and ERMS,
but mainly restricted to tumours lacking either a PAX3-FKHR or a
PAX7-FKHR fusion gene. PAX7 expression was detected at lower
levels in six out of 11 cases of RMS with PAX3/7-FKHR fusion
genes, whereas 15 out of 19 ARMS and ERMS cases lacking the
fusion genes expressed PAX7, generally at much higher levels
(Table 2 and Figure 1C). Expression of PAX7 was readily detectable
by real-time PCR and conventional RT–PCR in the control cell line
RDCL (no known translocation); however, levels of PAX7 detected
in many of the RMS samples with no known translocation were up
to 500 times greater than that of the control cell line (Table 2 and
Figure 1C). Adult-type PRMS expressed neither PAX3 nor PAX7.
As expected, expression of the fusion genes was restricted to
tumours known to harbour the relevant translocation, with relative
expression levels of PAX3-FKHR varying between 0.3- and 3.1-fold
and those for PAX7-FKHR between 0.8- and 2.1-fold. Expression of
MET was detected in 32 out of 37 RMS samples by RT–PCR
(Figure 2). All of the 19 RMS samples with no known translocation
and all four of the PRMS tumours were found to express MET
mRNA. All three of the tumours with PAX7-FKHR fusion genes
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Figure 1 Average relative expression of PAX3, PAX3-FKHR, PAX7 and PAX7-FKHR in RMS samples. (A) Expression of PAX3 is shown relative to the
expression of PAX3 in the cell line RDCL. (B) Expression of PAX3-FKHR is shown relative to the expression of PAX3-FKHR in the Rh30 cell line. (C)
Expression of PAX7 is shown relative to the expression of PAX7 in the cell line RDCL (note different scale due to high levels of expression relative to
RDCL¼1.0). (D) Expression of PAX7-FKHR is shown relative to the expression of PAX7-FKHR in the RMS sample 6. Translocation status is shown. Error
bars indicate standard deviation of four experiments.
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sexpressed MET mRNA, whereas this was not detected in five out of
nine samples with the PAX3-FKHR fusion.
DISCUSSION
We have investigated whether RMS samples without PAX-FKHR
fusion genes may have elevated levels of wild-type PAX3 or PAX7
expression, which might be implicated in tumorigenesis or
indicate cellular origin of the tumour, and have found that
elevated PAX3 expression levels are independent of RMS subtype
or presence of a PAX3/7-FKHR fusion gene. PAX3 expression was
detected in 16 out of 34 tumour samples, regardless of subtype or
translocation status, and it seems unlikely that a ‘dose’ effect of
PAX3 activity may confer a transformed phenotype in RMS in
which the PAX-FKHR fusion genes do not occur. However,
elevated levels of wild-type PAX7 expression are confined mainly
to RMS samples with no known translocation (excluding PRMS
cases). PAX7 and PAX3 expression levels in these RMS samples are
measured relative to expression levels in the RD cell line, which
expresses PAX7 levels comparable to those of normal human
myoblasts (Bernasconi et al, 1996).
These results agree with data showing PAX3 and PAX7
expression in ERMS cell lines published by Barr et al (1999) and
data from RMS specimens referred to therein. Elevated PAX7
expression in ERMS cell lines is also reported by Bernasconi et al
(1996). Here we show greatly elevated levels of PAX7 expression in
a large cohort of primary ERMS tumours, and generally lower, less
frequent expression of PAX7 in primary RMS tumours with PAX-
FKHR fusion genes. It is possible in ERMS that elevated wild-type
PAX7 expression contributes to transformation in the absence of
PAX3-FKHR or PAX7-FKHR expression, perhaps by suppressing
the apoptotic programme that would normally eliminate these cells
(Bernasconi et al, 1996). PAX3, PAX7 and their chimaeric
derivatives were not detected in any of the four PRMS samples
included in this study, suggesting that this subtype of RMS is
distinct from ERMS and ARMS. This is supported by the distinct
histopathology of these tumours and their prevalence in adult
rather than paediatric patients (Hollowood and Fletcher, 1994).
PAX7 expression during normal myogenesis is concurrent with
PAX3 expression; both genes appear to have the same DNA-
binding specificities and a high degree of functional redundancy
(Maulbecker and Gruss, 1993; Borycki et al, 1999). However,
elevated PAX7 expression in ERMS is not accompanied by elevated
PAX3 expression, suggesting that this tumour type is not derived
from proliferating myoblasts in the dermomyotome. Recent work
has shown that expression of PAX7 rather than PAX3 is required
for specification and maintenance of myogenic satellite cells (Seale
et al, 2000). These are a distinct lineage of myoblastic precursor
cells responsible for the postnatal growth, repair and maintenance
of skeletal muscle (Gussoni et al, 1999; Jackson et al, 1999; Seale
and Rudnicki, 2000). Analysis of PAX7
 /  transgenic mice
implicates PAX7 expression in the specification of myogenic
satellite cells from uncommitted side population (SP) stem cell
progenitors in skeletal muscle, where PAX7 expression may induce
satellite cell specification by restricting alternate developmental
programmes (Seale et al, 2000). PAX7 expression is an early event
during embryogenesis, and satellite cells are not restricted to the
somites or limb buds during early embryo development and can
move around the embryo (De Angelis et al, 1999; Asakura et al,
2002). Satellite cells proliferate in response to stimuli such as
exercise and injury, and descendents undergo several rounds of
cell division before differentiating into new multinucleate muscle
fibres (reviewed in Grounds and Yablonka-Reuveni, 1993; Bischoff,
1994; Buckingham, 2001).
PAX7 expression is implicated in the specification and
maintenance of satellite cells, and here we have shown that
PAX7 expression is almost completely restricted to RMS tumours
with no known translocation. We therefore propose that
these tumours may be derived from the myogenic satellite
cell lineage. This is consistent with the analysis of MET
expression by conventional RT–PCR, which shows expression of
MET mRNA in all 19 tumours with no known translocation:
quiescent satellite cells normally express MET, the receptor
for hepatocyte growth factor, prior to entering S-phase
(Cornelison and Wold, 1997). MET (c-met) is generally believed
to be a downstream target of PAX3, and it is unexpected to
find that MET is only expressed in four out of nine cases of
ARMS. However, Epstein et al (1996) have previously showed
that PAX3 and PAX3-FKHR expression only modestly increases
expression of c-met, and that PAX3-FKHR is not sufficient in
all cases to activate MET.
A recent mouse model for RMS has been described by Sharp et al
(2002) who report that HGF/SF Ink4A/Arf
 /  mice develop
multifocal sarcomatous malignancies arising from trunk and limb
skeletal muscles. In histopathological analysis, the tumours
resembled human ERMS, expressing low Pax3 levels, and elevated
Pax7 levels, which generally mirrored c-Met expression. They
describe the earlier appearance of hyperplastic satellite cells in the
skeletal muscle of these mice, and suggest that these myogenic
precursors were the source of the RMS tumours. The authors
propose that aberrant activation of the Pax7/c-Met pathways may
induce formation of ectopic skeletal muscle by encouraging
satellite-cell specification at the expense of alternate developmental
stem cell programmes.
These data from a novel mouse model of ERMS support our
proposal that in cases of human ERMS, elevated PAX7 expression
and consistent MET expression indicate an origin in myogenic
satellite cells for this subtype of RMS. The inherent on/off
proliferative capacity of these cells may increase their suscept-
ibility to transformation, and a distinct cell origin for this subtype
of RMS could explain its different behaviour and prognosis.
Molecular profiling of myogenic genes in satellite cells and RMS
with and without PAX-FKHR fusion genes should further define
the relation between these cell populations and provide insights
into the histogenesis and variable clinical behaviour of the
different subtypes of RMS.
12  
240 bp
 93 bp
 147 bp
Figure 2 RT–PCR to detect MET. Example of MET PCR product
(240bp) in lane 1, and restriction enzyme digest products (147, 93bp) in
lane 2.
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